Advancing CAR-T Therapies: The Importance of Closed Processes in Manufacturing and Future Innovations

New technologies and techniques for manufacturing CAR-T cells are expanding its application from cancer to autoimmune diseases and rare diseases. Research is quickly evolving, supported by scalable solutions, innovative products designed for Current Good Manufacturing Practice (CGMP) in cell therapy, and the use of closed and automatable instrumentation.

Chapters include:

A Closed, Autologous Bioprocess Optimized for TCR‐T Cell Therapies
TREM1/DAP12 Based Novel Multiple Chain CAR‐T Cells Targeting DLL3 Show Robust Anti‐tumor Efficacy for Small Cell Lung Cancer
Efficient CAR-T cell Manufacturing Using a Closed and Integrated Instrument Workflow
Streamlining Cell Therapy Manufacturing with Rapid and Reliable Bead Removal
An Automated 24‐hour CAR‐T Manufacturing Process

Download the Ebook

Your Company Email Address

Would you like to request pricing information or a product demo ?*

Opt In?

By completing this form you agree Citeline may contact you directly about industry news, products, services and events that may be of interest to you and Thermo Fisher Scientific group ( thermofisher.com/legal ) entities may contact you by e-mail and telephone to inform me of events, products, services and promotions offered in connection with the brands Thermo Scientific™, Applied Biosystems™, Invitrogen™, Gibco™, Ion Torrent™, Unity Lab Services™, Fisher Scientific™. You can unsubscribe at any time. Personal data will be used in accordance with Citeline’s Privacy notice and the Thermo Fisher Scientific Privacy Policy ( thermofisher.com/privacy policy)